These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1974840)

  • 1. Primary protection with beta-blockers in the treatment of hypertension.
    Coope J
    Drugs Exp Clin Res; 1990; 16(3):129-31. PubMed ID: 1974840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hypertension: risk-benefit ratio.
    Dollery CT
    J Hypertens Suppl; 1984 Dec; 2(2):S9-12. PubMed ID: 6152831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between antihypertensive agents, serum lipids and cigarette smoking in high risk hypertensive patients.
    Plouin PF
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():49-53; discussion 53-4. PubMed ID: 2575176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive effects on blood pressure at rest and during exercise of calcium antagonists, beta-receptor blockers, and their combination in hypertensive patients.
    Franz IW; Wiewel D
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1037-42. PubMed ID: 6085363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating hypertension. Are the right drugs given to the right patients?
    Beaulieu MD; Dufresne L; LeBlanc D
    Can Fam Physician; 1998 Feb; 44():294-8, 301-2. PubMed ID: 9512833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of exaggerated difference in morning and evening blood pressure measured by self-measured blood pressure monitoring in medicated hypertensive patients: Jichi Morning Hypertension Research (J-MORE) Study.
    Ishikawa J; Kario K; Hoshide S; Eguchi K; Morinari M; Kaneda R; Umeda Y; Ishikawa S; Kuroda T; Hojo Y; Shimada K;
    Am J Hypertens; 2005 Jul; 18(7):958-65. PubMed ID: 16053993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypertension management in general practice in Iceland].
    Jensdóttir JO; Sigurethsson EL; Thornorgeirsson G
    Laeknabladid; 2006 May; 92(5):375-80. PubMed ID: 16741320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistant hypertension: an overview.
    McAlister FA; Lewanczuk RZ; Teo KK
    Can J Cardiol; 1996 Sep; 12(9):822-8. PubMed ID: 8842136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies of calcium-channel blockers and beta-blockers in essential hypertension: clinical implications.
    Massie BM; Tubau JF; Szlachcic J
    Circulation; 1987 Jun; 75(6 Pt 2):V163-9. PubMed ID: 2882873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
    Hansson L
    J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.